|LETTERS TO EDITOR
|Year : 2017 | Volume
| Issue : 2 | Page : 213-214
Cushing's syndrome and treatment-resistant depression
Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India
|Date of Web Publication||28-Mar-2017|
Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bengaluru - 560 029, Karnataka
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Shukla L. Cushing's syndrome and treatment-resistant depression. Indian J Psychol Med 2017;39:213-4
Anil Kumar and Grover  report a case of Cushing's syndrome which presented as treatment-resistant depression. This report is instructive for diagnosis and management of Cushing's syndrome in treatment-resistant depression.
First, although, the title suggests that patient had “Cushing's syndrome,” the report does not mention any clinical or biochemical abnormalities suggestive of Cushing's syndrome except depression. Nonpsychiatric symptoms of Cushing's syndrome include central obesity, facial plethora, round face, purple striae, easy bruising of the skin, and muscle weakness. These symptoms are accompanied by clinical and biochemical signs of treatment-resistant hypertension, hyperglycemia, osteoporosis, hypokalemia, and nephrolithiasis. Thus, the diagnosis of Cushing's syndrome, in this case, rests solely on laboratory evidence of hypercortisolemia. Authors have reported raised plasma cortisol (722.7 nmol/L, laboratory reference: 193–634 nmol/L). Plasma cortisol has a well-defined circadian rhythm. Thus, it is important to mention the time at which sample was collected. Further, cortisol secretion increases during periods of stress like hospitalization and electro-convulsive therapy. For this reason, it is suggested that 24-h urinary free cortisol or midnight plasma cortisol should be used as a screening test for Cushing's syndrome. Authors also report dexamethasone nonsuppression, which is a frequently used test to diagnose Cushing's syndrome. The case report does not mention the protocol of dexamethasone suppression test used in this case. Importantly, nonsuppression of cortisol levels with low-dose dexamethasone (1 mg) is expected in patients suffering from severe depression. In such cases, a slightly cumbersome test which involves administration of 0.5 mg of dexamethasone at intervals of 6 h for 2 days and collection of two plasma samples is more appropriate. Keeping in mind, that this patient also had an adrenal mass suggestive of adrenal adenoma, it falls in a difficult to diagnose category called subclinical Cushing's syndrome with an “Incidentaloma”
Second, authors report complete remission of depression with a combination of venlafaxine 300 mg/day and ketoconazole 400 mg/day. There are important pharmacokinetic considerations involved in this combination. Venlafaxine is extensively metabolized to an active metabolite, desvenlafaxine mediated by cytochrome P 2D6 (CYP2D6). Venlafaxine and desvenlafaxine undergo transformation to inactive metabolites mediated by CYP3A4, CYP2C19, and CYP2C9. Ketoconazole is a strong CYP 3A4 inhibitor. Thus, a clinically significant interaction between Venlafaxine and Ketoconazole is likely. The magnitude of this interaction depends on CYP2D6 activity. CYP2D6 activity depends on multiple genetic polymorphisms. Lindh et al. have reported that venlafaxine exposure is doubled when administered with ketoconazole in subjects who are CYP2D6 poor metabolizers. At present, we do not have extensive data about CYP2D6 polymorphism in the Indian population, and poor metabolizers are reported at <1% frequency. Nevertheless, clinicians need to consider this possibility. A patient who has low CYP2D6 activity and receives venlafaxine and ketoconazole will be exposed to toxic concentrations of Venlafaxine. This can present as a sympathomimetic syndrome, cardiovascular instability, and life-threatening cardiac arrhythmias.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Anil Kumar BN, Grover S. Cushing's syndrome masquerading as treatment resistant depression. Indian J Psychol Med 2016;38:246-8.
] [Full text]
Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing's syndrome. Lancet 2006;367:1605-17.
Kumar A, Alcser K, Grunhaus L, Greden JF. Relationships of the dexamethasone suppression test to clinical severity and degree of melancholia. Biol Psychiatry 1986;21:436-44.
Cawood TJ, Hunt PJ, O'Shea D, Cole D, Soule S. Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? Eur J Endocrinol 2009;161:513-27.
Sangkuhl K, Stingl JC, Turpeinen M, Altman RB, Klein TE. PharmGKB summary: Venlafaxine pathway. Pharmacogenet Genomics 2014;24:62-72.
Lindh JD, Annas A, Meurling L, Dahl ML, AL-Shurbaji A. Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine. Eur J Clin Pharmacol 2003;59:401-6.
Umamaheswaran G, Kumar DK, Adithan C. Distribution of genetic polymorphisms of genes encoding drug metabolizing enzymes and drug transporters – A review with Indian perspective. Indian J Med Res 2014;139:27-65.
] [Full text]
Howell C, Wilson AD, Waring WS. Cardiovascular toxicity due to venlafaxine poisoning in adults: A review of 235 consecutive cases. Br J Clin Pharmacol 2007;64:192-7.